Table 1.

Demographic and medical characteristics of YACCS: participants versus non-participants/norm group

	Participants (N = 558)			Non-participants (N = 858)a				Norm group (N = 655)b
	M	SD	Range	M	SD	Range	p	M	SD	Range	p
Age at study (years)	25.78	3.33	18.10–30.97	25.48	3.45	18.01–31.00	0.10	24.75	3.79	18.01–30.99	< 0.001
Age at first diagnosis (years)	4.25	3.12	0.00–14.67	4.31	2.99	0.00–14.62	0.73
Time since first diagnosis (years)	20.92	3.31	15.02–29.17	21.18	3.42	14.81–30.93	0.16
	N		%	N		%	p	N		%	p
Sex							< 0.001				0.977
Male	273		48.9	530		61.8		321		49.0
Female	285		51.1	328		38.2		334		51.0
Age at first diagnosis (years)							0.86
0–5	418		74.9	644		75.1
6–11	128		22.9	199		23.2
12–15	12		2.2	15		1.7
Time since first diagnosis (years)							0.19
10–19	258		46.2	375		43.7
20–29	300		53.8	479		55.8
30–39	0		0.0	4		0.5
Diagnosisc							0.76
Leukemia/lymphoma	299		53.6	453		52.8
Solid tumor	198		35.5	300		35.0
CNS cancerd	61		10.9	105		12.2
Treatmente							0.10
Chemotherapy only (with/without surgery)	394		70.6	585		68.3
Radiotherapy only (with/without surgery)	14		2.5	33		3.9
Surgery alone	48		8.6	96		11.2
Combination therapy (chemo + radiotherapy, with/without surgery)	98		17.6	129		15.1
No treatment	4		0.7	14		1.6
Hematopoietic transplant							0.03
Yes	46		8.3	46		5.4
No	511		91.7	811		94.6
Relapse							0.63
Yes	61		10.9	101		11.8
No	497		89.1	757		88.2

Significant differences between participants and non-participants and between participants and norm group are presented in bold

^aYACCS who did not participate in the present study or any other part of the DCCS-LATER study part 2

^bThe norm group consists of young adults from the general Dutch population

^cFirst, primary diagnosis

^dCentral nervous system and miscellaneous intracranial and intraspinal neoplasm

^eFor primary cancers and recurrences